What is the long-term trend for Arrowhead Research's deferred revenue, net of current portion?

Over 3 years (2021 to 2025), Arrowhead Research's deferred revenue, net of current portion has grown at a -100.0% compound annual growth rate (CAGR), from $131.5M to $0.

Arrowhead Research ARWR Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Regeneron PharmaceuticalsREGN

$225.1M+6.3%

Ionis PharmaceuticalsIONS

——

BridgeBio PharmaBBIO

——

ModernaMRNA

——

ExelixisEXEL

——

Other financials

Income statement

See full

Revenue$73.7M-86.4%

Operating income-$141.3M-137%

Net income-$132.7M-136%

EPS (diluted)-$0.93-134%

Balance sheet

See full

Cash & equivalents$188.5M+1.5%

Total debt$107.9M-5.6%

Total equity$614.0M-10.1%

Total assets$2.3B+44.2%

Cash flow

See full

Operating cash flow$84.4M-81.6%

CapEx$2.6M-51.6%

Free cash flow$81.9M-82.0%

Valuation

See full

Market cap$11.52B+402%

Enterprise value$11.44B+418%

P/S18.5×+14.3×

Profitability

See full

Operating margin-35.7%+63.6pp

Net margin-48.4%+240pp

FCF margin1.8%+0.9pp

Returns & leverage

See full

Return on equity-46.4%+341pp

Debt / equity0.2×0.0×

Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arrowhead Research's deferred revenue, net of current portion?: Arrowhead Research (ARWR) reported deferred revenue, net of current portion of $48.62M in Q1 2026.
What is the long-term trend for Arrowhead Research's deferred revenue, net of current portion?: Over 3 years (2021 to 2025), Arrowhead Research's deferred revenue, net of current portion has grown at a -100.0% compound annual growth rate (CAGR), from $131.5M to $0.